It’s been another week of big news in the cannabis world.
We’ve been following all the big industry and policy news at Cannabis Wealth in a week which has seen some important developments.
Over at Cannabis Health, our in depth coverage of the ongoing growth of cannabis as a medical and wellness product continues.
Been busy and want to get caught up in a hurry?
Here are the six things you need to read to stay in the loop this week.
1. CBD market set to shrink
The UK’s CBD sector looks set to shrink significantly as the roll out of new regulations continues to batter the industry.
The FSA has confirmed to Cannabis Wealth it received applications for 803 different CBD products – but only 42 have been advanced to the next stage of the process so far.
More than half of all applications (445) were ‘incomplete’ and a further 41 have been withdrawn altogether.
Read the full story here.
2. CBD not linked to single doping case
CBD has not been linked to a single failed drugs test in UK sport despite fears about the undeclared levels of THC in some products.
The World Anti-Doping Agency removed the cannabinoid from its banned substances list in 2017 and since then several high profile athletes have publicly endorsed CBD products.
Even though CBD – which has no psychoactive properties – is not banned, the UK Anti-Doping (UKAD) still warns athletes to be cautious with treatments.
Read our exclusive report here.
3. School’s out for cannabis class
The first class on a pioneering university medical cannabis course have concluded their first year of studies.
The research programme at the Humboldt-Universitat zu Berlin examines the medical and nutritional uses of cannabis, production and the legal and economic frameworks of the business.
It’s the latest sign that medical cannabis is becoming a part of the mainstream education offering and a positive indication that new industry leaders will emerge in the coming years.
Full story here.
4. Reprieve for medical cannabis patients
The Department of Health has reached an agreement with Dutch officials to extend the supply of medical cannabis oils to existing patients in the UK until 2022.
Medical cannabis patients, living with severe, life-threatening epilepsy were left without access to medication when the UK left the EU at the end of last year.
Families, whose children are prescribed Bedrocan oils in the UK but must obtain their prescription through the Transvaal pharmacy in the Netherlands, were given two weeks notice that their medication could no longer be dispensed following the end of the Brexit transition period on 31, December 2020.
Read the full story.
5. UK largest’s medical cannabis trial reports back
The first findings from the UK’s largest medical cannabis patient study show quality of life improved by more than 50 percent.
Preliminary results from Drug Science’s Project Twenty21 study, have found medical cannabis significantly improves quality of life for people with life-limiting conditions such as chronic pain, multiple sclerosis (MS) Tourette’s syndrome and post-traumatic stress disorder (PTSD).
Published on Tuesday 11 May, the report is the first real-world data to be collected on medical cannabis in the UK.
Read more here.
6. Harrowing first-hand account of medical cannabis user
Diagnosed with a personality disorder and experiencing debilitating anxiety which left him housebound, Craig – whose name has been changed – had exhausted all treatment options and was losing all hope.
He speaks about how medical cannabis helped save his life here.